TY - JOUR
T1 - Infusion cisplatin chemotherapy and hyperfractionated thoracic radiotherapy for small-cell lung cancer
AU - Frytak, S.
AU - Shaw, E. G.
AU - Jett, J. R.
AU - Richardson, R. L.
AU - Foote, R. L.
AU - Creagan, E. T.
AU - Eagan, R. T.
AU - Su, J. Q.
PY - 1996/4
Y1 - 1996/4
N2 - Sixty patients, 29 with limited disease and 31 with extensive disease, received an infusion cisplatin-based chemotherapy regimen and, where applicable, subsequent hyperfractionated thoracic radiation therapy (HTRT). Of the patients with limited disease, the response rate was 100% (76% complete response); median survival 26.5 months; 1- and 2-year survival 90 and 55%, respectively. Of those with extensive disease, 96% responded (36% complete response) with median survival 12.0 months and 1- and 2-year survival 48 and 29%, respectively. Thirty-five percent of extensive disease patients were downstaged to a 'limited' status, with a median survival of 20.3 months. Grade IV leukopenia and thrombocytopenia were seen in 25 and 7% of patients, respectively, with one patient dying of radiation pneumonitis. Within the constraints of the study, infusion cisplatin-based chemotherapy and HTRT appear to be a safe and effective program for the treatment of small-cell lung cancer.
AB - Sixty patients, 29 with limited disease and 31 with extensive disease, received an infusion cisplatin-based chemotherapy regimen and, where applicable, subsequent hyperfractionated thoracic radiation therapy (HTRT). Of the patients with limited disease, the response rate was 100% (76% complete response); median survival 26.5 months; 1- and 2-year survival 90 and 55%, respectively. Of those with extensive disease, 96% responded (36% complete response) with median survival 12.0 months and 1- and 2-year survival 48 and 29%, respectively. Thirty-five percent of extensive disease patients were downstaged to a 'limited' status, with a median survival of 20.3 months. Grade IV leukopenia and thrombocytopenia were seen in 25 and 7% of patients, respectively, with one patient dying of radiation pneumonitis. Within the constraints of the study, infusion cisplatin-based chemotherapy and HTRT appear to be a safe and effective program for the treatment of small-cell lung cancer.
UR - http://www.scopus.com/inward/record.url?scp=0029986696&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029986696&partnerID=8YFLogxK
U2 - 10.1097/00000421-199604000-00022
DO - 10.1097/00000421-199604000-00022
M3 - Article
C2 - 8610649
AN - SCOPUS:0029986696
SN - 0277-3732
VL - 19
SP - 193
EP - 198
JO - American Journal of Clinical Oncology: Cancer Clinical Trials
JF - American Journal of Clinical Oncology: Cancer Clinical Trials
IS - 2
ER -